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■ SHORT COMMUNICATION ■
Introduction
Ovarian malignancy is highly suspected when patients
present with an ovarian cystic mass lesion accompanied
with ascites. However, aside from the primary origin,
the ovary is also a common site of metastasis from other
organs, such as the genital tract, gastrointestinal tract,
and breast. Differential diagnosis of primary or meta-
static ovarian cancers is sometimes difficult to achieve,
although in many cases of ovarian metastasis, there is a
known history of malignancy. Metastatic ovarian tumors
are thought to account for 10–30% of all malignant
ovarian tumors, but the precise incidence of ovarian
metastasis is unknown [1,2].
There have been several reports regarding metastatic
ovarian tumors that are diagnosed at autopsy and/or
surgery. The tumor may spread to the ovary via a blood-
borne, lymphatic route, transperitoneally or by direct
extension. Gastric carcinomas are the most frequent pri-
mary malignancy that metastasize to the ovary, through
a direct extension or “drop’’ metastasis mechanism. The
pathway of cancer cell metastasis from non-gynecologic
cancer to the ovary remains unclear except for cases 
of direct dissemination. Although advances in imaging
analysis have made it easier to find lesions, metastatic
ovarian tumors from non-gynecologic organs are rarely
diagnosed before primary treatment; therefore, their
prognosis is generally poor. Herein, we report the case
of a patient with breast cancer metastatic to the ovary,
with the manifestation of a left adnexal mass and
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ascites, and highlight the importance of considering
the possibility of ovarian tumors metastatic from non-
gynecologic organs.
Case Report
A 47-year-old woman, gravida 3, para 3, had been in
menopause for 5 years. She had a history of breast infil-
trating lobular carcinoma, right side, T3N0M0, grade 3,
which was treated with modified radical mastectomy
and axillary lymph-node dissection in July 2001. Post-
operatively, she received six cycles of adjuvant chemo-
therapy with complete remission. Then, oral tamoxifen
citrate was used for maintenance therapy.
Local tumor recurrence in the right breast was diag-
nosed in December 2003 and was treated with radio-
therapy. In March 2006, the patient experienced poor
appetite and abdominal fullness. A transabdominal
sonogram disclosed a 12-cm adnexal mass and ascites.
Tumor markers showed an elevated CA125 level
(180 U/mL) but normal CA153. She underwent explora-
tory laparotomy in May 2006, which revealed a left
12-cm ovarian mass and 300 mL of yellowish ascites.
Other evaluations showed nothing remarkable. Staging
surgery, including total hysterectomy, bilateral salpingo-
oophorectomy, partial omentectomy, and pelvic lymph-
node sampling were performed without incident (Table).
The final pathologic diagnosis was metastatic ovar-
ian cancer (Figures 1 and 2), similar to the original
breast carcinoma with marked discohesiveness resulting
in a pseudoalveolar pattern in many areas (Figure 3).
Meanwhile, the immunostaining profile performed on
the previous breast carcinoma and ovarian tumor
showed identical results: ER(+++), PR(+++), Her-2/
neu(−), and E-cadherin(−). That the other markers for
Figure 2. Cancer metastatic to the ovary with stromal
involvement. Metastatic tumor cells with similar morpho-
logic features similar to the primary breast tumor (black
arrow: Indian-file pattern) (hematoxylin and eosin, 100×).
Figure 1. Cancer metastatic to the ovary with stromal
involvement. The tumor cells occupy almost the entire ovary,
and no residual ovarian tissue is present in this area (hema-
toxylin and eosin, 40×).
Table. Characteristics and disease course of a 47-year-old patient with breast cancer metastatic to the ovary
Time (mo) Date Clinical events Treatment
0 July 2001 Right breast cancer (T3N0M0, Modified radical mastectomy +
grade 3)* axillary dissection
+1 August 2001 Chemotherapy started†
+8 March 2002 Tamoxifen citrate use
+28 December 2003 Right chest wall recurrence‡ Adjuvant external radiotherapy
Chest wall (50.4 Gy)
Scar boost (14 Gy)
+28 December 2003 Anastrozole use
+57 May 2006 Left ovarian metastasis Staging surgery§||
*Pathology: infiltrating lobular carcinoma, grade 3, estrogen receptors(++), progesterone receptors(+++); †5-fluorouracil 500 mg/m2 + epirubicin 50 mg/m2 +
cyclophosphamide 500–700 mg/m2 for six courses; ‡pathology: carcinoma recurrence, estrogen receptors(++), progesterone receptors(++), Her-2/neu(−); §stag-
ing surgery included total abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic lymph-node sampling and partial omentectomy; ||pathology: metastatic
breast cancer (tumor size, 12 × 7 × 6 cm), estrogen receptors(+++), progesterone receptors(+++), Her-2/neu(−).
primary ovary tumor were all negative further sup-
ported the diagnosis of metastatic carcinoma. On sur-
veillance examination, the patient was clinically without
evidence of disease.
Discussion
The ovaries are frequent targets of metastasis for
malignant tumors, as are the lung and liver. Besides
metastasis from gynecologic organs, the gastrointesti-
nal tract and breast cancers are the most common
non-gynecologic tumors metastatic to the ovaries [3–6].
Primary colon malignancies are the most common non-
gynecologic malignancy resulting in metastatic tumor
to the ovary, followed by malignancies of the appen-
dix, breast, and upper gastrointestinal tract. The aver-
age ovarian mass secondary to the metastatic tumor
has been shown to range from 9 to 12 cm in diameter,
which was also found in this case (a 12-cm solid 
ovarian tumor).
The Krukenberg tumor may be the typical metastatic
ovarian cancer and often arises from gastric cancers.
The World Health Organization reports that the fol-
lowing features should be present when making the
diagnosis of a Krukenberg tumor [7]: the presence 
of stromal involvement [8]; the presence of mucin-
producing neoplastic signet-ring cells [9]; and ovarian
stromal sarcomatoid proliferation [10]. In more recent
years, the term Krukenberg tumor has been more loosely
applied to describe any lesion metastatic to the ovary.
Patients with breast cancer are at increased risk of
developing ovarian cancer and vice versa. This is espe-
cially so in the subset of patients with a hereditary pre-
disposition to breast and ovarian cancer because of
BRCA1 or BRCA2 mutations [11]. With the increasing
risk of developing ovarian cancer in victims of breast
cancer, metastatic ovarian cancer from the breast can-
cer is also sometimes found, even accidentally during
prophylactic oophorectomy in patients with breast
cancer [12]. Breast cancer metastatic to the ovary is
often of the ductal or lobular type [12,13]. Ovarian
metastasis from the breast tends to be bilateral in
most cases [12,13], so it was easy to miss the diagnosis
of metastatic ovarian cancer in our case. Grossly, the
ovaries are usually enlarged, but only mildly so, with a
smooth surface and a bosselated nodular appearance.
Microscopically, the ovary reveals the typical patterns
associated with primary breast neoplasms. Sometimes,
it is difficult to make a differential diagnosis of primary
or metastatic ovarian cancer because ductal carcinoma
metastatic to the ovary may mimic a primary ovarian
endometrioid adenocarcinoma. Lobular carcinoma
within the ovary may be relatively subtle, and not obvi-
ous with scanning magnification. The rate of accurate
diagnosis can be improved by high-power field micro-
scopic examination because the metastatic lesion usually
reveals characteristic growth patterns, including Indian-
file arrangements, and characteristic cytologic features,
including intracytoplasmic lumina. In addition, signet
ring cells may be present.
CA125 is a tumor-associated antigen commonly
seen in ovarian carcinoma and is used to assess the
response to chemotherapy and for early detection of
relapse [14]. Elevations in serum CA125 have also
been documented in other tumors and non-malignant
disease [15]. Unlike other tumor markers such as car-
cinoembryonic antigen, data on CA125 in breast can-
cer is limited and its cause and significance have been
poorly defined. A limited role for the use of CA125
measurement may exist in metastatic breast cancer,
particularly in the population of patients with involve-
ment of the pleura or other coelomic-derived tissues,
in which CA125 levels are often elevated. In reviewing
all reports documenting the serologic values of CA125
in breast cancer in the English language literature, very
low detection rates were found (1–27%), and only one
study documented CA125 levels according to stage
[16]. At present, CA125 measurement in breast cancer
is likely to pose more questions than answers. Early
detection and treatment of metastatic breast cancer
with the aid of tumor markers, however, has not been
shown to improve outcome. The optimal use of this
marker in breast cancer remains ambiguous.
The prognosis of patients with breast cancer symp-
tomatically metastatic to the ovary is almost uniformly
poor, with actuarial 5-year survival rates of 0–27%
[17–20]. Surgery has a key role in the management of
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Figure 3. Breast infiltrating lobular carcinoma (primary
tumor) in Indian-file pattern; the tumor cells have relatively
small, uniform nucleus, and scanty cytoplasm (hematoxylin
and eosin, 200×).
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primary ovarian cancer; however, this has not been
clearly established in cancers metastatic to the ovaries.
There are discordant results regarding the role of surgi-
cal resection or tumoral debulking in patients with malig-
nancies metastatic to the ovaries. The 5-year survival
rates after resection of metastatic tumors in the ovaries
from gynecologic and non-gynecologic organs were sig-
nificantly different (47% vs. 19%) [21]. In the first report
evaluating the role of debulking surgery in patients
with breast cancer metastatic to the abdomen and
pelvis, Abu-Rustum et al reported that the median sur-
vival in patients with no gross residual disease after
operation was longer than that of patients with visible
residual disease, although this did not reach statistical
significance [22]. In addition, Eitan et al found that sur-
vival was better in optimally debulked patients (< 2 cm
of residual disease) than suboptimally debulked pa-
tients with breast cancer metastatic to the pelvis [23].
Surgical resection of breast cancer metastatic to the
abdomen and pelvis should be considered in candi-
date patients. In cases of pelvic tumors, metastatic
ovarian tumor should always be included in the differ-
ential diagnoses. If metastatic tumor is noted, cytore-
ductive surgery seems to have a beneficial effect on the
survival of selected patients.
In conclusion, the genital tract organs of patients
with breast cancer should be carefully and routinely
checked, not only for the possibility of endometrial
lesions secondary to tamoxifen citrate treatment, but
also for either primary or metastatic ovarian cancers.
Prompt and intensive treatment may prolong survival
and improve the quality of life.
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